Table 3 Responses to trabectedin per age group

From: Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

  

⩾60 Years

 
 

<60 Years

⩾60 Years

⩾70 Years

Total

 

n

%

n

%

n

%

n

%

 

267

76

83

24

24

7

350

100

CR

2

0.7

—

—

—

—

2

0.6

PR

25

9.4

8

9.6

1

4.2

33

9.4

SD

108

40.4

39

47.0

11

45.8

147

42.0

SD ⩾6 months

46

17.2

18

21.7

5

20.8

64

18.3

DCR

(CR+PR+SD ⩾6 months)

73

27.3

26

31.3

6

25.0

99

28.3

PD

121

45.3

31

37.3

10

41.7

152

43.4

NE patients

11

4.1

5

6.0

2

8.3

16

4.6

  1. Abbreviations: CR=complete response; DCR=disease control rate; NE=not evaluable; PD=progressive disease; PR=partial response; SD=stable disease.
Back to article page